On October 12, 2021, CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, a leading global growth equity firm, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital, alongside existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx. Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction.

The proceeds from the round will support the continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate in development for the treatment of hypertension, primary aldosteronism, and chronic kidney disease. The new funding will enable completion of the ongoing brigHTN Phase 2 clinical trial in patients with resistant hypertension as well as the ongoing Phase 2 Spark trial in hypertensive individuals with primary aldosteronism; in addition, it will support initiation of two new trials, a Phase 2 clinical trial (HALO) in patients with uncontrolled hypertension and a study of CIN-107’s impact on blood pressure and kidney function in patients with chronic kidney disease (CKD).

The Wilson Sonsini team that advised General Atlantic on the transaction include John Brust, Lowell Segal, Mike Hostetler, Julia Minitti, Luis Perla, and Amanda Creedon.

For more information, please see General Atlantic’s press release.